LifeMine Therapeutics raised $263 million across venture rounds to advance a potentially safer, more convenient immunosuppressant for transplant patients. The financing follows the company’s strategy of developing a fungus-mined biologic intended to reduce rejection while aiming to avoid some liabilities of existing immunosuppressive drugs. The raise includes an unannounced $75 million Series D in addition to previously disclosed rounds, expanding the company’s runway as it moves toward clinical evaluation. Serial biotech executive Greg Verdine’s leadership continues to anchor LifeMine’s platform approach. For the sector, the deal is a reminder of how transplant immunology remains commercially and clinically active for investors, especially when companies claim differentiated safety or administration advantages versus established regimens.